We're effectively close to ready to go, but readiness on paper means little in practice.
In the shadow of a virus most of the world had never named, East Africa's Bundibugyo Ebola outbreak has exposed a quiet gap in humanity's preparedness: decades of vaccine science, yet none of it approved for this particular strain. As the Democratic Republic of the Congo and Uganda count their dead and their borders prove permeable to the pathogen, researchers, institutions, and emergency funders have launched a simultaneous race across three vaccine platforms, multiple treatment trials, and an unprecedented prevention strategy — a reminder that readiness is not a fixed state but a perpetual negotiation between knowledge and time.
- A strain of Ebola with no approved vaccine has killed dozens and crossed an international border, exposing a critical blind spot in global epidemic preparedness.
- Three vaccine candidates from IAVI, Oxford, and Moderna are being fast-tracked with emergency funding, yet the fastest timeline still stretches months ahead while the outbreak spreads today.
- Existing monoclonal antibody treatments and antivirals offer a bridge — researchers are close to launching clinical trials, but an active conflict zone threatens to collapse the distance between 'ready on paper' and ready in practice.
- For the first time in any Ebola emergency, a daily antiviral pill is being tested as post-exposure prevention, a strategy that has never before been attempted and whose success depends on both drug efficacy and the speed of contact tracing in chaotic conditions.
- With over 400 confirmed cases, at least 49 deaths, and spread reaching Uganda's capital Kampala, the outbreak is no longer a remote crisis — it is a regional emergency unfolding faster than the tools to contain it can be assembled.
When Africa CDC named the Bundibugyo strain on May 15, most of the world was hearing the word for the first time. Within days, it had killed dozens in the Democratic Republic of the Congo and crossed into Uganda, reaching as far as Kampala. The WHO declared a public health emergency almost immediately — and a stark reality followed: no approved vaccine existed for this strain.
This was not a failure of vaccine science broadly. Two effective vaccines protect against the Zaire strain, responsible for the devastating 2014–16 and 2018–20 epidemics. But Bundibugyo is a distinct species of the same viral family, and approval cannot simply be transferred. With a fatality rate between 30 and 50 percent, the gap was urgent. By early June, the DRC had confirmed over 320 cases with more than 100 suspected; Uganda reported 15 cases and at least one death.
The Coalition for Epidemic Preparedness Innovations moved quickly, funding three parallel vaccine efforts. IAVI's rVSV Bundibugyo — built on the same platform as the existing Zaire vaccine and considered the most promising by WHO — received $3.2 million, though human trials remain seven to nine months away. Oxford's ChAdOx1 Bundibugyo, backed by $8.6 million and using the same technology as the Oxford-AstraZeneca Covid vaccine, could begin trials within two to three months, pending more animal data. Moderna, with $50 million, is developing an mRNA candidate it says could reach trials within months.
While vaccines remain on the horizon, researchers are preparing to test what already exists. Two monoclonal antibody treatments — MBP134 and Maftivimab — and the antiviral remdesivir have shown promise. A trial called Partners is being readied to compare their effectiveness. Investigators describe themselves as close to ready, but operationalizing safely inside a conflict zone remains the defining obstacle.
Perhaps most remarkably, an antiviral pill called obdeldesivir is being tested as a post-exposure prevention drug — the first time such a strategy has been attempted in an Ebola outbreak. Given daily for ten days after exposure, it showed up to 100 percent protection in animal studies against two other strains. Whether it can replicate that in human contact tracing conditions remains the open question. The outbreak has become, in effect, an urgent and sprawling experiment in pandemic response — one where the virus does not wait for the science to catch up.
When the Africa Centres for Disease Control announced a new Ebola outbreak on May 15, they named a virus most of the world had never heard of: Bundibugyo. By early June, it had claimed at least 48 lives in the Democratic Republic of the Congo and spread across the border into Uganda, where cases appeared even in Kampala, far from the outbreak's origin. The World Health Organization declared a public health emergency within two days. And almost immediately, a problem became clear: the world had no approved vaccine for this particular strain.
This was not a failure of vaccine science. Ebola vaccines exist. Two of them work well against the Zaire strain, which killed thousands during the 2014-16 West Africa epidemic and again in 2018-20. Merck's Ervebo and Johnson & Johnson's two-dose regimen of Zabdeno and Mvabea have proven effective. But Bundibugyo is a different species of the same virus family, and a vaccine designed for one cannot simply be deployed against another without testing and formal approval. The Bundibugyo strain carries a death rate between 30 and 50 percent—lower than Zaire's 50 to 70 percent, but still catastrophic. By June 2, the DRC had confirmed 321 cases with 116 more suspected. Uganda reported 15 cases and at least one death.
The race to fill that gap began immediately. The Coalition for Epidemic Preparedness Innovations committed emergency funding to three vaccine candidates, each using a different technological approach. IAVI received $3.2 million for a vaccine called rVSV Bundibugyo, which uses the same harmless animal virus platform as the existing Zaire vaccine. The WHO called it the most promising candidate, but it would take seven to nine months before doses were ready for human trials. IAVI's president, Mark Feinberg, said the organization was pushing to compress that timeline. Oxford University, working with the Serum Institute of India, received $8.6 million for ChAdOx1 Bundibugyo, which uses the same modified chimpanzee virus technology that underpinned the Oxford-AstraZeneca Covid vaccine. This one could move faster—trials might begin within two or three months, though WHO experts wanted more animal data first. Moderna, with $50 million in emergency funding, was developing an mRNA vaccine, the same platform that became familiar during the pandemic. The company said it could have a vaccine ready for trials within months.
While waiting for vaccines, researchers were preparing to test existing medicines. Three drugs showed potential: two monoclonal antibody treatments called MBP134 and Maftivimab, which work by mimicking the immune system's response, and remdesivir, an antiviral. The WHO's independent experts recommended using MBP134 in the current outbreak. Amanda Rojek, an associate professor at the UK's Pandemic Sciences Institute, was helping prepare a trial called Partners to compare which treatment worked best. The medicines already existed, and investigators were seeking regulatory approval in both the DRC and Uganda. "We're effectively close to ready to go," Rojek said. But readiness on paper meant little in practice. Researchers still had to ensure patient safety, staff safety, and proper clinical conditions in an active conflict zone. "Making sure that we can operationalise safely" was the key hurdle, Rojek explained. Basic supportive care—hydration, blood pressure management, the kind of care you might give someone with severe flu—remained the foundation of treatment.
For the first time in an Ebola outbreak, doctors were also preparing to test a prevention drug. Obdeldesivir, an antiviral pill, had shown up to 100 percent protection in monkeys against two other Ebola strains when given daily for ten days within 24 hours of exposure. The idea was to give it to people who had been in contact with confirmed cases and see whether it stopped them from getting sick. Christophe Fraser of Oxford University, who would lead that trial, noted that results would depend on both how well the drug worked and how quickly field teams could identify and monitor the right contacts. "A trial goes quicker if the intervention is very effective," he said. "If it is less effective, then it takes longer." The outbreak had created an urgent, sprawling experiment in pandemic response—three vaccines in parallel development, existing drugs being tested in real time, a prevention strategy never before attempted in an Ebola emergency, all unfolding in a region where the virus was still spreading and the border between two countries offered no real barrier to its movement.
Notable Quotes
We're effectively close to ready to go.— Amanda Rojek, associate professor of health emergencies, UK Pandemic Sciences Institute
A trial goes quicker if the intervention is very effective. If it is less effective, then it takes longer.— Christophe Fraser, Oxford University, on the prevention drug trial
The Hearth Conversation Another angle on the story
Why does a vaccine that works for one Ebola strain not work for another? They're the same virus, aren't they?
They're related, but not the same. Think of it like influenza—a flu vaccine for one strain won't protect you against a different one. Bundibugyo and Zaire are different species within the Ebola family. A vaccine trains your immune system to recognize a specific shape, a specific genetic signature. Change the virus, and you have to retrain the immune system. That's why you can't just use the existing vaccines.
So these three new vaccines—IAVI, Oxford, Moderna—they're all starting from scratch?
Not entirely from scratch. IAVI is using the same proven platform as the existing Zaire vaccine, just adapted for Bundibugyo. Oxford is using the same technology as their Covid vaccine. Moderna is using mRNA. They're not inventing new approaches; they're adapting proven ones. But yes, each one has to be tested, approved, manufactured. That takes time.
How much time? The outbreak is happening now.
IAVI says seven to nine months before doses are ready for trials. Oxford thinks two or three months. Moderna says months. But those are optimistic timelines. In the meantime, researchers are testing existing drugs—antibody treatments, antivirals—that might help people who are already sick.
And this prevention drug, obdeldesivir—that's new?
New to Ebola outbreaks, yes. It's an antiviral pill. In animal studies, it protected monkeys almost completely if given within 24 hours of exposure. The idea is to give it to people who've been in contact with confirmed cases, to stop them from getting sick in the first place. It's never been tried in a real outbreak before.
What's the catch?
Everything moves slower in a conflict zone. You have to keep your teams safe. You have to make sure patients are getting proper supportive care before you start testing new drugs. You have to find the right people to give the prevention drug to, and then follow them to see if it works. The science is ready. The logistics are the hard part.